Fewer than 10% of patients eligible to benefit from obesity jabs including Wegovy have access to them, states the World Health Organization as it issues its first recommendations on the medications.
With over a billion people worldwide now living with obesity, it is advocating for more widespread and fairer availability to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"The latest guidance affirms that obesity is a lifelong illness that can be addressed with comprehensive and ongoing care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are significant obstacles to universal availability to the injections that can assist patients in reducing significant weight, notes the agency.
Skinny Jab Scarcity
Even under the present most favorable case, the supply of such drugs could only cover about 100 million people – under 10% of the global need, as stated by the health organization.
The advice calls on nations and manufacturers to widen access, by measures such as licensing agreements.
Exclusive production rights on the active ingredient – the main ingredient of the drug Wegovy – is set to lapse in a number of nations in 2026.
The Way Weight-Loss Drugs Function
The injections mimick a body's own hormone to slow digestion, suppress the appetite and enhance feelings of fullness so people reduce food intake.
Individuals typically begin shedding pounds in the initial weeks of beginning the weekly injections.
Research points to users may put most of the weight back on after a year of stopping the treatment, when their typical hunger return.
Being carrying excess weight increases your likelihood for contracting diseases, including diabetes, heart disease, brain attack, and some malignancies.
Excess weight concerns individuals in all nations and was linked to 3.7 million fatalities worldwide in 2024, according to the WHO.
